The sensitive and specific detection of premalignant and malignant lesions is a crucial and indispensable prerequisite for optimal treatment outcome and prognosis. Surgical biopsy, which is currently the primary diagnostic tool, often causes patient anxiety and discomfort, undesirable side effects, and sampling errors. For example, multiple prostate biopsies miss up to 30% of cancer present at the time of biopsy.
1, 2, 3 An urgent need exists to develop cost-effective, minimally invasive imaging technologies to identify premalignancy and malignancy with high sensitivity and specificity.
4 Optical imaging tools such as reflectance confocal microscopy, optical coherence tomography (OCT), and optical coherence microscopy (OCM) are promising diagnostic tools for detecting cancer at an early stage.
5 Optical imaging is particularly useful for
in vivo applications because it uses near-infrared wavelengths
that avoid predominant absorption in tissue.
6